The effect of needle and syringe program and opioid agonist therapy on the risk of HIV, hepatitis B and C virus infection for people who inject drugs in Amsterdam, the Netherlands: findings from an emulated target trial
- 31 March 2021
- Vol. 116 (11) , 3115-3126
Abstract
Background and aims: Major declines in HIV and hepatitis C and B virus (HCV/HBV) incidence among people who inject drugs (PWID) have been attributed to early implementation of harm‐reduction programs (HRP) in the Netherlands, but alternative factors such as selective mortality and demographic and drug market shifts over time probably contributed to observed incidence declines. We quantified and tested the effect of HRP participation on risk of these infections among PWID in Amsterdam, the Netherlands. Design: We emulated the design of a hypothetical, ideal randomized trial using observational data from the Amsterdam Cohort Studies (1985–2014). Setting: Amsterdam, the Netherlands. Participants: We included PWID who ever used opioids, had a recent history of injecting drug use (IDU) and tested negative for HIV, HCV or HBV. Of 983 participants, 640, 137 and 308 were included for the HIV, HCV and HBV analyses and 59, 45 and 49 seroconversions were observed, respectively. Interventions: Intervention arms were: complete HRP participation [≥ 60 mg/day methadone and 100% needle and syringe program (NSP) coverage, or any methadone dose if no recent injection drug use] versus no HRP and partial HRP participation combined (< 60 methadone mg/day and/or < 100% NSP coverage). Conclusions: Complete participation in harm reduction programs appears to have led to substantial decreases in HIV and hepatitis C and B virus acquisition risk among people who inject drugs in the Netherlands. Measurements: Separately for each infection, we estimated the hazard ratios (HR) comparing HRP arms using marginal structural models. Findings: Compared with no/partial HRP participation, complete HRP participation led to lower risk of HIV [HR = 0.54, 95% confidence interval (CI) = 0.27–1.08], HCV (HR = 0.16, 95% CI = 0.06–0.40) and HBV (HR = 0.28, 95% CI = 0.13–0.61) acquisition.Keywords
This publication has 36 references indexed in Scilit:
- Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspectiveHarm Reduction Journal, 2021
- Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic reviewThe Lancet Global Health, 2017
- Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta‐analysisAddiction, 2017
- Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studiesBMJ, 2017
- Effectiveness of Methadone Maintenance Therapy and Improvement in Quality of Life Following a Decade of ImplementationJournal of Substance Abuse Treatment, 2016
- Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectivenessInternational Journal of Drug Policy, 2014
- Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?Addiction, 2013
- Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug usersAddiction, 2007
- Large decline in injecting drug use in Amsterdam, 1986–1998: explanatory mechanisms and determinants of injecting transitionsJournal of Epidemiology and Community Health, 2001
- The ‘methadone by bus’ project in AmsterdamBritish Journal of Addiction, 1990